Jennifer R. Brown, MD, PhD, discusses the interim results of the SEQUOIA trial , which investigated the combination of zanubrutinib and venetoclax for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.
Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at the Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discusses the interim results of the SEQUOIA trial (NCT03336333), which investigated the combination of zanubrutinib (Brukinsa) and venetoclax (Venclexta) for patients with treatment-naïve chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
The multiarm, randomized phase 3 trial evaluated the efficacy and safety of the next-generation Bruton’s tyrosine kinase inhibitor zanubrutinib in separate cohorts of patients with and without deletion 17p (del[17p]), which is linked to higher risk in CLL. Patients in the del(17p) arm received zanubrutinib followed by venetoclax until reaching disease progression, unacceptable toxicity, or undetectable minimum residual disease status.
According to Brown, interim results of 36 patients with del(17p) who received zanubrutinib were presented at the American Society of Hematology annual meeting in December 2021, out of approximately 80 planned patients that were enrolled. Of the 35 who were evaluable, 30 had a response, for an overall response rate (ORR) of 96.8% (95% CI, 69.7%-95.2%). The median follow-up was 11.2 months. A complete response (CR) was observed in 4 patients (12.9%).
Grade 3 or higher adverse events (AEs) were reported in 37.1% of patients. One patient left due to being diagnosed with lung cancer, 1 ended treatment due to localized disease progression, and another due to withdrawal of consent. All others remained on treatment, while others have yet to be evaluated by bone marrow biopsy, according to Brown.
TRANSCRIPTION:
0:08 | There were 36 patients evaluable for response. The first response evaluation is after the first 3 months of zanubrutinib. And then there were 0 response evaluations thereafter. So the median follow-up is [about] 12 months. The ORR is 97% already, which is really quite remarkable, especially given the high-risk patient population, but perhaps not too surprising, because we're combining 2 of our best agents that we have in CLL. So I think that's really quite exciting. Thus far, there's only been 1 progression event, which was a localized progression without disease in other compartments. So that is also relatively good.
The CR rate is 14%, but that's still a moving target because patients need to be evaluated by bone marrow biopsy when they get a CR. And so there are other patients who potentially qualify who haven't been evaluated by bone marrow biopsy yet.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More